Lansoprazole

Indications
 Oral
Peptic ulcer
Adult: 30 mg once daily in the morning given for 4 wk (duodenal ulcer) or for 8 wk (gastric ulcer).
Hepatic impairment: Severe impairment: Max dose: 30 mg/day.
Oral
Hypersecretory conditions
Adult: Initially, 60 mg daily and adjust as required. Daily doses >120 mg should be given in 2 divided doses.
Hepatic impairment: Severe impairment: Max dose: 30 mg/day.
Oral
Acid-related dyspepsia
Adult: 15-30 mg once daily in the morning for 2-4 wk.
Hepatic impairment: Severe impairment: Max dose: 30 mg/day.
Oral
Gastro-oesophageal reflux disease
Adult: 30 mg once daily in the morning for 4-8 wk. Maintenance: 15-30 mg once daily according to response.
Child: and erosive oesophagitis: 1-11 yr: ≤30 kg: 15 mg once daily; >30 kg: 30 mg once daily. May increase doses up to 30 mg bid if patient is still symptomatic after 2 or more wk of treatment. 12-17 yr: For erosive oesophagitis: 30 mg once daily for up to 8 wk; For nonerosive gastro-oesophageal reflux disease: 15 mg once daily for up to 8 wk.
Hepatic impairment: Severe impairment: Max dose: 30 mg/day.
Oral
NSAID-associated ulceration
Adult: 15-30 mg daily for 4-8 wk.
Hepatic impairment: Severe impairment: Max dose: 30 mg/day.
Oral
Prophylaxis of NSAID-induced ulcers
Adult: 15-30 mg daily for 4-8 wk.
Hepatic impairment: Severe impairment: Max dose: 30 mg/day.
Oral
H.pylori infection
Adult: 1-wk triple therapy: 30 mg bid combined with clarithromycin 500 mg bid and either amoxicillin 1 g bid or metronidazole 400 mg bid.
Hepatic impairment: Severe impairment: Max dose: 30 mg/day.
Intravenous
Erosive oesophagitis
Adult: 30 mg over 30 minutes daily for up to 7 days.
Hepatic impairment: Consider dose adjustment.

Special Populations: Patients with severe hepatic impairment: Max dose: 30 mg daily.
Warnings / Precautions
 Hepatic impairment. Gastric malignancy should be ruled out. Pregnancy and lactation.
Adverse Reactions
 Diarrhoea, abdominal pain, nausea, constipation, headache, dizziness, eosinophilia, myalgia, glossitis, stomatitis, rash.
Drug Interactions
 Reduced bioavailability with antacids and sucralfate. May decrease the absorption of atazanavir, itraconazole and ketoconazole. May increase plasma concentration of cilostazol.
See Below for More lansoprazole Drug Interactions
Mechanism of Actions
 Lansoprazole inhibits gastric acid secretion by inhibiting the H+/K+ ATPase, which is also known as the proton pump. Both basal and stimulated acid are inhibited.
Absorption: Rapidly absorbed from the GIT (oral); peak plasma concentrations after 1.5 hr.
Distribution: Protein-binding: 97%.
Metabolism: Extensively hepatic; converted to 5-hydroxyl-lansoprazole and lansoprazole sulfone.
Excretion: Via faeces (main) and urine (15-30% of a dose); 1-2 hr (elimination half-life).
Administration
 Should be taken on an empty stomach. (Take before meals.)
Storage Conditions
 Intravenous: Store at 25°C (77°F). Oral: Store at 25°C (77°F).
ATC Classification
 A02BC03 - lansoprazole ; Belongs to the class of proton pump inhibitors. Used in the treatment of peptic ulcer and gastro-oesophageal reflux disease (GERD).
Storage
 Intravenous: Store at 25°C (77°F). Oral: Store at 25°C (77°F).
Available As
  • Lansoprazole 15 mg
  • Lansoprazole 15 mg (2 cap)
  • Lansoprazole 30 mg
  • Lansoprazole 30 mg (2 cap)

    • Subscribe for latest updates

    Subscribe to our e-mail newsletter to receive updates.

    No comments yet.

    Post Review about Lansoprazole


    Lansoprazole Containing Brands

    We are Developing Our database, More results coming soon.

    Lansoprazole is used in following diseases

    We are Developing Our database, More results coming soon.

    Drug - Drug Interactions of Lansoprazole

    We are Developing Our database, More results coming soon.